1. Home
  2. SWKH vs TARA Comparison

SWKH vs TARA Comparison

Compare SWKH & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SWKH
  • TARA
  • Stock Information
  • Founded
  • SWKH 1996
  • TARA N/A
  • Country
  • SWKH United States
  • TARA United States
  • Employees
  • SWKH N/A
  • TARA N/A
  • Industry
  • SWKH Diversified Financial Services
  • TARA Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • SWKH Finance
  • TARA Health Care
  • Exchange
  • SWKH Nasdaq
  • TARA Nasdaq
  • Market Cap
  • SWKH 201.5M
  • TARA 202.8M
  • IPO Year
  • SWKH 1999
  • TARA N/A
  • Fundamental
  • Price
  • SWKH $16.39
  • TARA $4.55
  • Analyst Decision
  • SWKH
  • TARA Strong Buy
  • Analyst Count
  • SWKH 0
  • TARA 3
  • Target Price
  • SWKH N/A
  • TARA $22.67
  • AVG Volume (30 Days)
  • SWKH 8.6K
  • TARA 523.2K
  • Earning Date
  • SWKH 11-14-2024
  • TARA 03-12-2025
  • Dividend Yield
  • SWKH N/A
  • TARA N/A
  • EPS Growth
  • SWKH N/A
  • TARA N/A
  • EPS
  • SWKH 0.84
  • TARA N/A
  • Revenue
  • SWKH $24,725,000.00
  • TARA N/A
  • Revenue This Year
  • SWKH N/A
  • TARA N/A
  • Revenue Next Year
  • SWKH $6.17
  • TARA N/A
  • P/E Ratio
  • SWKH $19.54
  • TARA N/A
  • Revenue Growth
  • SWKH N/A
  • TARA N/A
  • 52 Week Low
  • SWKH $15.14
  • TARA $1.60
  • 52 Week High
  • SWKH $18.49
  • TARA $10.48
  • Technical
  • Relative Strength Index (RSI)
  • SWKH 53.54
  • TARA 41.78
  • Support Level
  • SWKH $16.25
  • TARA $5.04
  • Resistance Level
  • SWKH $16.64
  • TARA $6.20
  • Average True Range (ATR)
  • SWKH 0.35
  • TARA 0.40
  • MACD
  • SWKH 0.05
  • TARA -0.22
  • Stochastic Oscillator
  • SWKH 78.07
  • TARA 2.37

About SWKH SWK Holdings Corporation

SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.

About TARA Protara Therapeutics Inc.

Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).

Share on Social Networks: